文献速递骨软组织肉瘤与黑色素瘤

美国晚期黑色素瘤患者免疫治疗输注时间对总生存的影响(MEMOIR):一项单中心纵向研究的倾向评分匹配分析

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
PubMed 文献 · Lancet Oncol · 2021-11-12

MEMOIR 单中心纵向研究纳入 2012 至 2020 年 299 例 IV 期黑色素瘤患者,中位随访 27 个月;每增加 20% 在 16:30 后输注免疫检查点抑制剂,总生存 HR 为 1.31(95%CI 1.00–1.71;p=0.046)。倾向评分匹配后,至少 20% 输注在傍晚者总生存更短(中位 4.8 年 vs 未达到;HR 2.04,95%CI 1.04–4.00;p=0.038)。

要点

  • 每增加 20% 在 16:30 后输注免疫检查点抑制剂,总生存 HR 1.31(95%CI 1.00–1.71;p=0.046)。
  • 匹配后至少 20% 输注在傍晚者中位总生存 4.8 年 vs 未达到(HR 2.04;p=0.038)。
  • 作者认为可考虑在多学科管理中安排输注在下午中段之前,但需前瞻性研究。

核心结论

  • 研究结果与越来越多证据一致:适应性免疫反应在傍晚初始刺激时不如白天强。
  • 虽然免疫检查点抑制剂输注时间的前瞻性研究是必要的,但在晚期黑色素瘤的多学科管理中可考虑努力将输注安排在下午中段之前。

研究设计与样本

  • MEMOIR 是一项在单一三级癌症中心(美国佐治亚州亚特兰大埃默里大学 Winship 癌症研究所)开展的纵向研究,纳入所有接受伊匹木单抗、纳武利尤单抗或帕博利珠单抗或这些药物联合治疗的黑色素瘤患者。
  • 本分析从 MEMOIR 数据库收集 2012 年至 2020 年间诊断为 IV 期黑色素瘤的成人(年龄≥18 岁)去标识化参与者水平数据,排除接受少于四次输注者。
  • 使用标准治疗剂量,治疗医师可自行调整;主要结局为总生存,定义为任何原因死亡,从首次免疫检查点抑制剂输注日期开始计算。
  • 采用 Cox 回归和倾向评分匹配(匹配年龄、东部肿瘤协作组体能状态、血清乳酸脱氢酶浓度、接受皮质类固醇和放疗)分析总生存与 16:30 后输注比例之间的关联;同时评估导致免疫检查点抑制剂更换或停用的治疗相关不良事件。

主要发现

  • 2012 年 1 月 1 日至 2020 年 12 月 31 日期间,481 例黑色素瘤患者在研究中心的接受免疫检查点抑制剂治疗,其中 299 例为 IV 期疾病并纳入本研究;中位随访 27 个月(IQR 14–47)。
  • 在完整未匹配样本中,102 例(34%)为女性,197 例(66%)为男性,中位年龄 61 岁(IQR 51–72)。
  • 每增加 20% 的免疫检查点抑制剂输注在 16:30 后接受(占患者所有输注的比例),总生存风险比(HR)为 1.31(95%CI 1.00–1.71;p=0.046)。
  • 倾向评分匹配分析中,接受至少 20% 输注在 16:30 后的患者(n=73)与未接受者(n=73)比较(146 例中女性 54 例[37%],男性 92 例[63%],中位年龄 58 岁[IQR 48–68]),至少 20% 输注在傍晚与更短的总生存相关(中位 4.8 年[95%CI 3.9–不可估计] vs 未达到;HR 2.04[1.04–4.00;p=0.038])。
  • 该结果在多变量比例风险调整中保持稳健:纳入完整未匹配研究样本时 HR 1.80(1.08–2.98;p=0.023),不纳入时 HR 2.16(1.10–4.25;p=0.025)。

临床怎么用

  • 作者认为,尽管免疫检查点抑制剂输注时间的前瞻性研究是必要的,但在晚期黑色素瘤的多学科管理中可考虑努力将输注安排在下午中段之前。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications. We aimed to determine whether specific time-of-day patterns of immune checkpoint inhibitor infusions might alter melanoma treatment efficacy. METHODS: Melanoma Outcomes Following Immunotherapy (MEMOIR) is a longitudinal study of all patients with melanoma who received ipilimumab, nivolumab, or pembrolizumab, or a combination of these at a single tertiary cancer centre (Winship Cancer Institute of Emory University, Atlanta, GA, USA). For this analysis, we collected deidentified participant-level data from the MEMOIR database for adults (age ≥18 years) diagnosed with stage IV melanoma between 2012 and 2020. Those who received fewer than four infusions were excluded. Standard of care doses were used, with modifications at the treating physicians' discretion. The primary outcome was overall survival, defined as death from any cause and indexed from date of first infusion of immune checkpoint inhibitor. We calculated the association between overall survival and proportion of infusions of immune checkpoint inhibitors received after 1630 h (a composite time cutoff derived from seminal studies of the immune-circadian rhythm to represent onset of evening) using Cox regression and propensity score-matching on age, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase concentration, and receipt of corticosteroids and radiotherapy. Treatment-related adverse events that led to change or discontinuation of immune checkpoint inhibitors were also assessed. FINDINGS: Between Jan 1, 2012, and Dec 31, 2020, 481 patients with melanoma received treatment with immune checkpoint inhibitors at the study centre, of whom 299 had stage IV disease and were included in this study; median follow-up was 27 months (IQR 14 to 47). In the complete unmatched sample, 102 (34%) patients were female and 197 (66%) were male, with a median age of 61 years (IQR 51 to 72). Every additional 20% of infusions of immune checkpoint inhibitors received after 1630 h (among all infusions received by a patient) conferred an overall survival hazard ratio (HR) of 1·31 (95% CI 1·00 to 1·71; p=0·046). A propensity score-matched analysis of patients who did (n=73) and did not (n=73) receive at least 20% of their infusions of immune checkpoint inhibitors after 1630 h (54 [37%] of 146 patients were women and 92 [63%] were men, with a median age of 58 years [IQR 48 to 68]) showed that having at least 20% of infusions in the evening was associated with shorter overall survival (median 4·8 years [95% CI 3·9 to not estimable] vs not reached; HR 2·04 [1·04 to 4·00; p=0·038]). This result remained robust to multivariable proportional hazards adjustment with (HR 1·80 [1·08 to 2·98; p=0·023]) and without (2·16 [1·10 to 4·25; p=0·025]) inclusion of the complete unmatched study sample. The most common adverse events were colitis (54 [18%] of 299 patients), hepatitis (27 [9%]), and hypophysitis (15 [5%]), and there were no treatment-related deaths. INTERPRETATION: Our findings are in line with an increasing body of evidence that adaptive immune responses are less robust when initially stimulated in the evening than if stimulated in the daytime. Although prospective studies of the timing of immune checkpoint inhibitor infusions are warranted, efforts towards scheduling infusions before mid-afternoon could be considered in the multidisciplinary management of advanced melanoma. FUNDING: National Institutes of Health, American Society for Radiation Oncology and Melanoma Research Alliance, and Winship Cancer Institute.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Qian DC, Kleber T, Brammer B, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021. PMID: 34780711. doi:10.1016/S1470-2045(21)00546-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。